comparemela.com

Latest Breaking News On - Expanding horizons - Page 16 : comparemela.com

HER2-Directed Agents in NSCLC

Dr Wade Thomas Iams explains how trastuzumab deruxtecan became the standard-of-care for HER2-mutated non-small cell lung cancer.

Wade thomas iamsExpanding horizonsAntibody drug conjugatesNon small cell lung cancerDirected agents

Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer

Martin Dietrich, MD, PhD, details the molecular target CEACAM5 and its use in the treatment of patients with non-small cell lung cancer.

Martin dietrichExpanding horizonsAntibody drug conjugatesNon small cell lung cancerNon small cell lungLung cancer

Cloud Deployment Models: Exploring The Different Ways To Harness The Power Of The Cloud

Cloud deployment models play a crucial role in determining how organizations utilize cloud resources to achieve their goals.

Community cloudCollaborative cloud solutionsCloud service providersCloud deploymentUnleashing enhanced securityCollaborative cloudExpanding horizonsDeployment modelsCloud scalabilityCloud cost efficiencyCloud data securityCloud complianceRight cloud deploymentWorkload requirementsData sensitivityCompliance requirements

ADCs in Development for the Treatment of Lung Cancer

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Wade thomas iamsMartin dietrichExpanding horizonsAntibody drug conjugatesNon small cell lung cancer

Overview of Antibody Drug Conjugates in Lung Cancer

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.

Wade thomas iamsExpanding horizonsAntibody drug conjugatesNon small cell lung cancerThomas iams

vimarsana © 2020. All Rights Reserved.